192650-25-2

Basic information

• Product Name: 2,4-Hexanedione, 6-(4-nitrophenyl)-
• CAS NO: 192650-25-2
• Molecular Formula: C12H13NO4
• Molecular Weight: 235.24
• Mol File: 192650-25-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2,4-Hexanedione, 6-(4-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Hexanedione, 6-(4-nitrophenyl)-(192650-25-2)
• EPA Substance Registry System: 2,4-Hexanedione, 6-(4-nitrophenyl)-(192650-25-2)

Safety Data

• Hazardous Substances Data: 192650-25-2(Hazardous Substances Data)

Upstream product

• 123-54-6 acetylacetone 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 107324-93-6 3-(p-nitrophenyl)propanoyl chloride 
• 16642-79-8 3-(4-nitrophenyl)propionic acid 
• 1363334-41-1 C₁₇H₂₁NO₆ 

Downstream Products

• 782475-33-6 C₁₆H₂₁NO₆ 
• 1363334-43-3 C₂₆H₄₂N₃O₆⁽¹⁺⁾*Cl^(1-) 
• 1363334-40-0 C₂₂H₃₄N₃O₄⁽¹⁺⁾*Cl^(1-) 
• 1363334-42-2 C₂₁H₂₉NO₇ 
• 905569-07-5 C₁₄H₁₇NO₅ 
• 192650-26-3 4-[4-(3,5-dioxo-hexyl)-phenylcarbamoyl]-butyric acid 
• 220689-91-8 C₁₂H₁₅NO₂ 
• 929088-03-9 3-[4-(2-{2-[2-(2-{2-[4-(3,5-dioxo-hexyl)-phenylcarbamoyl]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-phenyl]-N-[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-N-methyl-propionamide 
• 929088-02-8 N-[4-(3,5-dioxo-hexyl)-phenyl]-3-{2-[2-(2-{2-[4-({[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methyl)-phenoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-propionamide 
• 929087-93-4 N-(2'-(isoxazol-5-ylsulfamoyl)-4-{2-[2-(2-{2-[2-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenylcarbamoyl)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-biphenyl-2-ylmethyl)-3,3,N-trimethyl-butyramide 
• 929087-89-8 3-(2-{2-[2-({[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methoxy)-ethoxy]-ethoxy}-ethoxy)-N-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenyl)-propionamide 
• 929087-81-0 N-[4-(2-{2-[2-(2-{2-[4-(3,5-dioxo-hexyl)-phenylcarbamoyl]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-2'-(isoxazol-5-ylsulfamoyl)-biphenyl-2-ylmethyl]-3,3,N-trimethyl-butyramide 
• 929087-92-3 3-{2-[2-(2-{2-[2-formyl-2'-(isoxazol-5-ylsulfamoyl)-biphenyl-4-yloxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-N-(4-{2-[2-(2-methyl-[1,3]dioxolan-2-ylmethyl)-[1,3]dioxolan-2-yl]-ethyl}-phenyl)-propionamide 
• 929087-80-9 N-[4-(3,5-dioxo-hexyl)-phenyl]-3-(2-{2-[2-({[2'-(isoxazol-5-ylsulfamoyl)-4-oxazol-2-yl-biphenyl-2-ylmethyl]-methyl-carbamoyl}-methoxy)-ethoxy]-ethoxy}-ethoxy)-propionamide 

Relevant articles and documents

Synthesis of a novel analytical reagent for the determination of active sites for conjugation on a catalytic aldolase monoclonal antibody

An optimized and scalable synthesis of a novel analytical reagent for the determination of the number of active sites available for conjugation on a catalytic aldolase monoclonal antibody (mAb) is described. The original conditions suffered from lack of reproducibility, incomplete reactions, and required several chromatographies and lyophilizations that afforded material of low purity. A redesigned route and optimized protocols have been developed that eliminate the use of toxic and unsafe reagents such as HMPA and HATU. In addition, the number of chromatographies has been reduced to only one and time-consuming and energy-intensive lyophilizations are no longer required. The overall yield has been considerably improved from the original 4% to 20% after telescoping the last two steps of the synthesis and this new approach allowed for the preparation of material with higher chemical purity (≥99% vs the initial 90%) to meet specifications.

ANTI-ANGIOGENIC COMPOUNDS

The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

Anti-angiogenic compounds

The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.